David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long summarize their discussion of Inflammatory Bowel Disease (IBD) and discuss prospective advances in treatment options.
The panel concludes the discussion with key takeaways on the evolving treatment landscape for COPD.
A history of bariatric surgery was associated with up to 50% reduced risk of PDAC among a national cohort.
Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai share advice for improving psoriasis care for patients with skin of color.
Andrea Nguyen, PA, shares her clinical pearls on taking care of patients with AD.
Lawrence F. Eichenfield, MD; Jeffrey M. Bienstock, MD, FAAP; Peter A. Lio, MD; and Elizabeth A. Swanson, MD, review additional mechanisms being investigated in the pipeline for the treatment of atopic dermatitis.
Closing their discussion on insomnia, panelists share final thoughts and advice for community physicians.
A panel of dermatologists have a comprehensive discussion on exciting developments in the treatment of plaque psoriasis, focusing on treatment approaches, patient monitoring strategies, and recent clinical trial data.
The panel of experts focus on strategies for distinguishing primary biliary cholangitis (PBC) from other liver diseases with similar clinical presentations, emphasizing key diagnostic markers and assessment techniques.
A panel of expert cardiologists share their clinical pearls for managing patients with hyperlipidemia.
In part 3 of our Special Report on lipoprotein apheresis, Sperling and Gianos discuss future considerations for use and the evolving landscape of lipid management.
Wally Smith, MD, shares his take-home points for patients with sickle cell disease and urges to get tested for sickle cell trait.
Key opinion leaders emphasize important considerations when discussing the safety of anti-VEGF agents with patients and highlight unmet needs in nonproliferative diabetic retinopathy treatments.
Panelists discuss the efficacy and safety data for ritlecitinib and deuruxolitinib in treating alopecia areata, highlighting that ritlecitinib achieved SALT scores of ≤20 in 23% of patients at week 24 compared to 1.6% in the placebo group, while deuruxolitinib showed SALT scores of ≤20 in 42.5% (8mg BID ) and 56.8% (12mg BID) of patients, with treatment-emergent adverse events primarily being mild to moderate, including upper respiratory tract infections and headaches for ritlecitinib, and headache and acne for deuruxolitinib.
In this Q&A, Vinod Chandran, MBBS, MD, DM, PhD, discussed a method to analyze biomarkers that may differentiate patients with psoriasis and psoriatic arthritis.
Steven D. Schwartz, MD, reviews challenges and unmet needs in treatment of patients with neovascular AMD and DME.
Dermatologists Drs Tina Bhutani and Scott Boswell and patient Kanya Oul share resources and tools available to cope with generalized pustular psoriasis (GPP).
A longtime clinician writes on the signs and risks of fatal heart attack events, including the Widowmaker.
Geoffrey Grammer, MD closes this series highlighting the administration options of esketamine, its safety profile, and the importance of monitoring patients using this treatment.
In this MEDcast episode, Drs Soloman, Sharobeem, Boone and Feldman discuss the use of step therapy in rheumatoid arthritis, how step therapy was intended to be used, how it is actually used, and challenges and solutions to its use.
Closing out its discussion on atopic dermatitis, the panel considers best practices and unmet needs in the treatment landscape.
Concluding their discussion on sickle cell disease management, expert panelists share key unmet needs and hopes for the future.
Anjali Tiku Owens, MD, shares insights into how their institution or clinic implements the Risk Evaluation and Mitigation Strategy (REMS) program for mavacamten, detailing the requirements and responsibilities of the patient in the process. Additionally, the expert draws upon their real-world experience with the cardio myosin inhibitor (CMI) in clinical practice, providing valuable perspectives on the practical application of this novel drug class.
In part 5 of our 5-part discussion, experts discuss their perspective on appropriate guidance for screening age and the future of CRC advocacy.
ADHD experts share their final thoughts on the treatment and management of ADHD.
Thought leaders in diabetes provide closing remarks about the importance of continuous awareness of glycemic control in patients as well as the need for effective communication between patients and providers.
Strategies to avoid complications of sickle cell disease and ensure non-dependency on opioids when treating patients for pain as a result of the disease.